Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma

Sun, Jianguo, Lei, Yuan, Dai, Zhaoxing, Liu, Xi, Huang, Taomin, Wu, Jihong, Xu, Zhi Ping and Sun, Xinghuai (2017) Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma. ACS Applied Materials and Interfaces, 9 9: 7990-7999. doi:10.1021/acsami.6b16509


Author Sun, Jianguo
Lei, Yuan
Dai, Zhaoxing
Liu, Xi
Huang, Taomin
Wu, Jihong
Xu, Zhi Ping
Sun, Xinghuai
Title Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma
Journal name ACS Applied Materials and Interfaces   Check publisher's open access policy
ISSN 1944-8252
1944-8244
Publication date 2017-03-08
Sub-type Article (original research)
DOI 10.1021/acsami.6b16509
Open Access Status Not yet assessed
Volume 9
Issue 9
Start page 7990
End page 7999
Total pages 10
Place of publication Washington, DC, United States
Publisher American Chemical Society
Collection year 2018
Language eng
Formatted abstract
A novel layered double hydroxide (LDH) nanoparticle/thermogel composite drug delivery system (DDS) for sustained release of brimonidine (Bri) has been designed, prepared, and characterized in this study for treatment of severe glaucoma. Brimonidine is first loaded onto LDH (Bri@LDH) nanoparticles, which are then dispersed in the thermogel consisting of plenty of micelles based on poly(dl-lactic acid-co-coglycolic acid)-polyethylene glycol-poly(dl-lactic acid-co-coglycolic acid) (PLGA-PEG-PLGA) copolymer. The Bri@LDH/Thermogel DDS containing 125.0 μg/g of brimonidine has been found to sustainably release the drug for up to 144 h, significantly extending the drug release period compared to that from Bri@LDH nanoparticles. The Bri@LDH/Thermogel DDS is not cytotoxic to human corneal epithelial cells and shows good biocompatibility. In vivo drug release from the special contact lens made of Bri@LDH/Thermogel DDS has been sustained for at least 7 days, which more effectively modulates the relief of intraocular pressure (IOP). Thus, the Bri@LDH/Thermogel DDS is a promising drug delivery alternative that can be used for treatment of severe glaucoma.
Keyword Brimonidine
Drug delivery system (DDS)
Glaucoma
Intraocular pressure (IOP)
Layered double hydroxide (LDH) nanoparticles
Thermogel
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Australian Institute for Bioengineering and Nanotechnology Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 28 Mar 2017, 00:20:19 EST by Web Cron on behalf of Learning and Research Services (UQ Library)